Mid-sized European drugmakers are snapping up US biotechs. Will the surge continue?

European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.